Cytotoxic T Cells from Human Immunodeficiency Virus Type 2-infected Patients Frequently Cross-react with Different Human Immunodeficiency Virus Type 1 Clades

Overview

Journal J Virol

Publisher American Society for Microbiology

Date 1998 Mar 14

PMID 9499105

Citations 18

Authors

A Bertoletti

F Cham

S McAdam

T Rostron

S Rowland-Jones

S Sabally

T Corrah

K Ariyoshi

H Whittle

Affiliations

Soon will be listed here.

Abstract

Knowledge of immune mechanisms responsible for the cross-protection between highly divergent viruses such as human immunodeficiency virus type 1 (HIV-1) and HIV-2 may contribute to an understanding of whether virus variability may be overcome in the design of vaccine candidates which are broadly protective across the HIV subtypes. We demonstrate that despite the significant difference in virus amino acid sequence, the majority of HIV-2-infected individuals with different HLA molecules possess a dominant cytotoxic T-cell response which is able to recognize HIV-1 Gag protein. Furthermore, HLA-B5801-positive subjects show broad cross-recognition of HIV-1 subtypes since they mounted a T-cell response that tolerated extensive amino acid substitutions within HLA-B5801-restricted HIV-1 and HIV-2 epitopes. These results suggests that HLA-B5801-positive HIV-2-infected individuals have an enhanced ability to react with HIV-1 that could play a role in cross-protection.

Citing Articles

Co-Infections and Superinfections between HIV-1 and Other Human Viruses at the Cellular Level.

Acchioni C, Sandini S, Acchioni M, Sgarbanti M Pathogens. 2024; 13(5).

PMID: 38787201 PMC: 11124504. DOI: 10.3390/pathogens13050349.

HIV-2 inhibits HIV-1 gene expression via two independent mechanisms during cellular co-infection.

Yapo V, Majumder K, Tedbury P, Wen X, Ong Y, Johnson M J Virol. 2023; 97(12):e0187022.

PMID: 37991365 PMC: 10734542. DOI: 10.1128/jvi.01870-22.

HIV-2 as a model to identify a functional HIV cure.

Esbjornsson J, Jansson M, Jespersen S, Mansson F, Honge B, Lindman J AIDS Res Ther. 2019; 16(1):24.

PMID: 31484562 PMC: 6727498. DOI: 10.1186/s12981-019-0239-x.

Inhibitory Effects of HIV-2 Vpx on Replication of HIV-1.

Mahdi M, Szojka Z, Motyan J, Tozser J J Virol. 2018; 92(14).

PMID: 29743354 PMC: 6026746. DOI: 10.1128/JVI.00554-18.

Regulation of HIV-Gag expression and targeting to the endolysosomal/secretory pathway by the luminal domain of lysosomal-associated membrane protein (LAMP-1) enhance Gag-specific immune response.

Godinho R, Matassoli F, Lucas C, Rigato P, Goncalves J, Sato M PLoS One. 2014; 9(6):e99887.

PMID: 24932692 PMC: 4059647. DOI: 10.1371/journal.pone.0099887.

References

Rowland-Jones S, Sutton J, Ariyoshi K, Dong T, Gotch F, McAdam S . HIV-specific cytotoxic T-cells in HIV-exposed but uninfected Gambian women. Nat Med. 1995; 1(1):59-64. DOI: 10.1038/nm0195-59. View

Ariyoshi K, Cham F, Berry N, Jaffar S, Sabally S, Corrah T . HIV-2-specific cytotoxic T-lymphocyte activity is inversely related to proviral load. AIDS. 1995; 9(6):555-9. DOI: 10.1097/00002030-199506000-00004. View

Gallimore A, Cranage M, Cook N, Almond N, Bootman J, Rud E . Early suppression of SIV replication by CD8+ nef-specific cytotoxic T cells in vaccinated macaques. Nat Med. 1995; 1(11):1167-73. DOI: 10.1038/nm1195-1167. View

Maryanski J, Jongeneel C, Bucher P, Casanova J, Walker P . Single-cell PCR analysis of TCR repertoires selected by antigen in vivo: a high magnitude CD8 response is comprised of very few clones. Immunity. 1996; 4(1):47-55. DOI: 10.1016/s1074-7613(00)80297-6. View

Kersh G, Allen P . Essential flexibility in the T-cell recognition of antigen. Nature. 1996; 380(6574):495-8. DOI: 10.1038/380495a0. View

Valitutti S, Muller S, Dessing M, Lanzavecchia A . Different responses are elicited in cytotoxic T lymphocytes by different levels of T cell receptor occupancy. J Exp Med. 1996; 183(4):1917-21. PMC: 2192499. DOI: 10.1084/jem.183.4.1917. View

Marlink R . Lessons from the second AIDS virus, HIV-2. AIDS. 1996; 10(7):689-99. DOI: 10.1097/00002030-199606001-00002. View

Bunce M, ONeill C, Barnardo M, Krausa P, Browning M, Morris P . Phototyping: comprehensive DNA typing for HLA-A, B, C, DRB1, DRB3, DRB4, DRB5 & DQB1 by PCR with 144 primer mixes utilizing sequence-specific primers (PCR-SSP). Tissue Antigens. 1995; 46(5):355-67. DOI: 10.1111/j.1399-0039.1995.tb03127.x. View

Flynn J, Keating P, Hosie M, Mackett M, Stephens E, Beatty J . Env-specific CTL predominate in cats protected from feline immunodeficiency virus infection by vaccination. J Immunol. 1996; 157(8):3658-65. View

10.

Garboczi D, Ghosh P, Utz U, Fan Q, Biddison W, Wiley D . Structure of the complex between human T-cell receptor, viral peptide and HLA-A2. Nature. 1996; 384(6605):134-41. DOI: 10.1038/384134a0. View

11.

Goulder P, Bunce M, Krausa P, McIntyre K, Crowley S, Morgan B . Novel, cross-restricted, conserved, and immunodominant cytotoxic T lymphocyte epitopes in slow progressors in HIV type 1 infection. AIDS Res Hum Retroviruses. 1996; 12(18):1691-8. DOI: 10.1089/aid.1996.12.1691. View

12.

Wilson C, Kalams S, Wilkes B, Ruhl D, Gao F, Hahn B . Overlapping epitopes in human immunodeficiency virus type 1 gp120 presented by HLA A, B, and C molecules: effects of viral variation on cytotoxic T-lymphocyte recognition. J Virol. 1997; 71(2):1256-64. PMC: 191180. DOI: 10.1128/JVI.71.2.1256-1264.1997. View

13.

POULSEN A, Aaby P, Larsen O, Jensen H, Naucler A, Lisse I . 9-year HIV-2-associated mortality in an urban community in Bissau, west Africa. Lancet. 1997; 349(9056):911-4. DOI: 10.1016/S0140-6736(96)04402-9. View

14.

Aaby P, POULSEN A, Larsen O, Christiansen C, Jensen H, Melbye M . Does HIV-2 protect against HIV-1 infection?. AIDS. 1997; 11(7):939-40. View

15.

Ariyoshi K, Loeff M, Sabally S, Cham F, Corrah T, Whittle H . Does HIV-2 infection provide cross-protection against HIV-1 infection?. AIDS. 1997; 11(8):1053-4. View

16.

McAdam S, Kaleebu P, Krausa P, Goulder P, French N, Collin B . Cross-clade recognition of p55 by cytotoxic T lymphocytes in HIV-1 infection. AIDS. 1998; 12(6):571-9. DOI: 10.1097/00002030-199806000-00005. View

17.

Guyader M, Emerman M, Sonigo P, Clavel F, Montagnier L, Alizon M . Genome organization and transactivation of the human immunodeficiency virus type 2. Nature. 1987; 326(6114):662-9. DOI: 10.1038/326662a0. View

18.

Moss B, Flexner C . Vaccinia virus expression vectors. Annu Rev Immunol. 1987; 5:305-24. DOI: 10.1146/annurev.iy.05.040187.001513. View

19.

Tedder R, OConnor T, Hughes A, NJie H, Corrah T, Whittle H . Envelope cross-reactivity in Western blot for HIV-1 and HIV-2 may not indicate dual infection. Lancet. 1988; 2(8617):927-30. DOI: 10.1016/s0140-6736(88)92598-6. View

20.

Nixon D, Townsend A, Elvin J, Rizza C, Gallwey J, McMichael A . HIV-1 gag-specific cytotoxic T lymphocytes defined with recombinant vaccinia virus and synthetic peptides. Nature. 1988; 336(6198):484-7. DOI: 10.1038/336484a0. View